Home · Business · Nov 20 archive
Bayer Settles Roundup Cancer Claims for Up to $7.25 Billion
Confirmed
In Short: A Missouri judge on Friday approved a $7.25 billion settlement by Bayer to resolve thousands of claims from U.S. Cancer patients who say the company should have warned them that its popular weed killer Roundup could cause lymphoma.

A Missouri judge on Friday approved a $7.25 billion settlement by Bayer to resolve thousands of claims from U.S. Cancer patients who say the company should have warned them that its popular weed killer Roundup could cause lymphoma.
Louis Circuit Judge Timothy Boyer said the settlement is “a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation.” Bayer CEO Bill Anderson said the settlement is “a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation.”
The settlement calls for Bayer to make annual payments into a special fund for up to 21 years, totaling as much as $7.25 billion. The settlement includes $600 million for attorneys’ fees.
Some attorneys have said the individual settlement amounts are too small and the terms too restrictive. However, others argue the deal is better than getting nothing, which became a heightened likelihood after the Supreme Court ruling in June that Bayer cannot be sued in state courts on claims it failed to warn about cancer.
The nationwide settlement applies both to Roundup users who already are ill and those who become diagnosed with non-Hodgkin lymphoma in future years. Bayer already has changed the formula for its Roundup version sold to residential users and is phasing out Roundup for US residential use in 2023.
Though some attorneys for cancer patients contend the settlement payouts are too small, others argue the deal is better than getting nothing, which became a heightened likelihood after the Supreme Court ruling.
The settlement is the scariest, worst future settlement that’s ever been contemplated, according to attorney Gerson Smoger. The verdict “should send a strong signal” that plaintiffs “will face significant challenges” pursuing Roundup-related cancer claims in the future, said Bill Dodero, Bayer’s U.S. General counsel and global litigation leader.
Bayer has spent billions of dollars settling thousands of cases linked to Roundup since it acquired the weedkiller's producer, the US agrichemical group Monsanto, in 2018.
Bayer is facing approximately 65,000 claims in state and federal courts from plaintiffs who say they developed cancer after using Roundup at home or on the job.
What this adds
The settlement is a significant financial burden for Bayer but provides a resolution to the ongoing litigation.
What's confirmed
- Bayer CEO Bill Anderson said in a statement that the court-approved settlement is “a decisive milestone in the company’s strategy to mitigate the risks of both pending and future Roundup litigation.” Missouri-based Monsanto debuted Roundup weed killer in 1974 with the chemical glyphosate as its active ingredient.
- The settlement calls for Bayer to make annual payments into a special fund for up to 21 years, totaling as much as $7.25 billion.
- Bayer has spent billions of dollars settling thousands of cases linked to Roundup since it acquired the weedkiller's producer, the US agrichemical group Monsanto, in 2018.
What's still developing
- Supreme Court undercut one of the central arguments in the Roundup lawsuits.
- The court noted it had processed a certificate of dissolution of marriage but that a settlement agreement was still pending and that a judge needed to review everything.
- But, he said, the settlement is a "strong solution that protects competition and consumers."
